Stem Cell Clinic

Doctors: Live or cadaver donors can now save the life of a Rockton … – Rockford Register Star

Five years after being diagnosed with a rare autoimmune disease and told he would need a triple transplant to survive; Rockton resident Joe Beard has some positive news to share.

Beard, 42, a husband and father of two young daughters, suffers from STAT3 gain of function, a multiorgan autoimmune disease that is actually attacking his own body.

He is on home dialysis and is in need of a liver, kidney and bone marrow transplant.

More:'This is going to kill me': Rockton man with rare genetic disorder in need of 2 live donors

Outside of a recent stint in the hospital to stop internal bleeding in his abdomen, not much has changed physically in the past year for Beard. But emotionally? His spirits are as high as ever.

Earlier this year, Beard learned that Dr. Andres Duarte, a liver specialist at the University of Pittsburgh Medical Center who was working on Beard's case, is now based in Chicago serving as director of the Northwestern Medicine Organ Transplantation Center.

Having Duarte located in Chicago is significant for several reasons:

Beard and his wife, Hayley, have already met with Duarte and other doctors in Chicago.

"The head guy was almost giddy with excitement," Beard said. "I mean it was just like, 'Wow! Maybe this is God's plan. Meet Dr. Duarte and then two years later, follow him out here to Chicago.'"

At the time of Beard's diagnosis in 2018 there were only 28 known cases of STAT3 gain of function.

Hayley, Beard's wife of nine years, has already agreed to donate up to 60% of her liver, the only organ in the human body capable of re-growing.Liver regeneration after donation takes six to eight weeks.

What is still needed is a kidney donor. If the kidney comes from a live donor, that person also will likely be asked to be the bone marrow donor, too.

"So,right now, the plan is to proceed with my care at Northwestern," Beard said, "and we're just asking people to sign up to be a donor for a kidney or stem cell and to share the story."

To register to be a donor, you can do so at nmlivingdonor.org.

To help the family with travel and expenses, donations can be sent to:

Roscoe United Methodist Church, C/O Joseph Beard Transplant Fund, 10816 Main St., Roscoe, Illinois, 61073

Chris Green: 815-987-1241; cgreen@rrstar.com; @chrisfgreen

Read the original here:
Doctors: Live or cadaver donors can now save the life of a Rockton ... - Rockford Register Star

What Is Hyperbaric Oxygen Therapy (HBOT)? Forbes Health – Forbes

The use of hyperbaric medical therapy can be traced back to the late 1600s in Britain, but HBOT was not used widely until after World War II, when it was utilized to treat decompression sickness in divers. Since that time, scientific research into the methods and uses of HBOT has been ongoing, with hundreds of facilities providing this therapy since the early 2000s.

Fundamentally, HBOT [delivers] oxygen at greater concentrations than those naturally available in the atmosphere, explains Ahmet Ergin, M.D., an endocrinologist at Heart & Family Health Institute in Florida. Increasing the atmospheric pressure during an HBOT treatment session allows more oxygen to dissolve into the bloodstream, enabling the healing and regeneration of damaged or injured tissues, according to Ergin.

Through this process, HBOT not only increases oxygen concentration, but also reduces inflammation, speeds recovery time and lessens pain, according to Dr. Ergin.

During hyperbaric oxygen therapy, a patient breathes 100% oxygen intermittently while the whole body is pressurized within a hyperbaric chamber to at least 1.4 atmospheres absolute (ATA), explains Dr. Renie Guilliod, a rehabilitation specialist at UT Southwestern Medical Center in Texas and director of the Hyperbaric Medicine Program at the Institute for Exercise and Environmental Medicine. ATA is a unit of measurement used to describe the sum of barometric (air) and hydrostatic (fluid) pressures used in hyperbaric oxygen therapy.

With HBOT, we deliver higher amounts of oxygen to the body by increasing the driving pressure of O2 from the lungs through the blood to the tissues, says Dr. Guilliod.

This oxygen delivery results in intermittent hyperoxygenation, which means ones oxygen levels in the blood are higher for a short period. The increase in blood oxygen levels has been demonstrated to promote the healing of injured tissues and can be used for several conditions.

HBOT is part of the Undersea and Hyperbaric Medicine Society (UHMS). The American Board of Medical Specialties recognizes it under the umbrella of the American Board of Preventive Medicine (ABPM) and the American Board of Emergency Medicine (ABEM).

View original post here:
What Is Hyperbaric Oxygen Therapy (HBOT)? Forbes Health - Forbes

Clinical Commentary: Addressing Treatment Tactics in Blastic … – Targeted Oncology

Gary J. Schiller, MD

Director, Bone Marrow/Stem Cell Transplantation

Professor, Hematology-Oncology

David Geffen School of Medicine at UCLA

Los Angeles, CA

I have a lot of patients in my clinic with [BPDCN], but in general, it is a rare disease [that clinicians] may not see for many years in their practice. Its true epidemiology is not known because [clinicians] didnt know how to identify it, so it is historically rare. To make it even more difficult, there was a change in nomenclature by the [World Health Organization] back in 2016.1 A lot of older practitionersand Im one of those older practitionerswould call this [disease] some sort of lymphoid leukemia with cutaneous manifestations.

There is a lot of difficulty in recognizing this disease clinically and pathologically, and its more recent that [the targets of] CD4, CD56, and CD123 expression [were] all identified as pathognomonic.2 Right now, we think this constitutes less than half a percent of all hematologic malignancies and less than a percent of [patients with] cutaneous lymphoma.

We believe there are [approximately] 4 cases per 10 million population, so that gives you an idea of rarity, but I think that we dont know because we havent had a strong diagnostic bed of criteria until [approximately] 2016. Weve been doing this for [approximately] 5 or 6 years, and knowledge will increase when weve gone past a decade with homogeneous diagnostic criteria.

How BPDCN Presents

[This disease] is characterized by production of clonal plasmacytoid dendritic cells. These cells are characteristic with their expression pattern and are a little more common in the older population, even [for patients older than] 70 years.3

Many of the patients are older men, but not exclusively, as Im taking care of a young [woman] right now [who is] in her 30s, so this epidemiology is also bound to change if they have an antecedent hematologic disorder that is rare.

The primary sits of involvement are skin, bone marrow, peripheral blood, lymph nodes, leptomeninges, and extramedullary sites such as in the muscle behind the retroperitoneum also occur. Early recognition is challenging, as the clinical features are also challenging and can overlap with other diseases, and there are delays between the onset of the skin rash and the diagnosis.

[Those] who see this in the field are internists, dermatologists, and hematologists and oncologists after a while, [and they can miss] this diagnosis unfortunately. The typical journey for a patient with this condition is that they start having continuous lesions and are then examined by a primary care physician for a while, and they may or may not be identified as having something that requires immediate biopsy evaluation. When the patient develops pancytopenia, thats when the referral occurs, and the median time to final diagnosis is often 6 months.

However, this disease is highly aggressive when its not treated with specific agents, and the survival is 6 to 18 months.4 [Clinicians] have tried all kinds of treatments, such as vincristine, steroids, treating it like its acute lymphocytic leukemia, or treating it now like one would acute myeloid leukemiawith venetoclax [Venclexta] and azacitidine [Onureg]. But without specific therapy, the survival is short.

Cutaneous Features of BPDCN

The cutaneous features vary a little, but most patients present with some nodule that is described as dark purple, brown, or [bruised]. Sometimes they can have plaques, but I view them as basically little hemorrhages that are in the form of nodules or plaques that are often disseminated, typically sparing the dermis.

Skin biopsies that include the deep dermis and subcutaneous fat are very important to making a diagnosis, but as I say, usually the disease involves the peripheral blood and bone marrow, so there are easier ways to make a diagnosis than taking a deep tissue biopsy.4

Some of our patients do have localized manifestations and a localized geography. The other differential diagnoses include extramedullary hematopoiesis and some malignant neoplasms. This disease can spread broadly like a leukemia, and its not unusual for patients to have splenomegaly. What Im dealing with right now with a patient of mine is leptomeningeal involvement with cranial neuropathy. That is not a rare thing, [its a] typical kind of leptomeningeal leukemia in that patients have cranial nerve findings at the base of the brain.5

Other sites of the disease include sinus, tongue, breast tissue, gallbladder, [and] muscle, so this disease can spread broadly. Initial evaluationof course, besides the usual history, physical, and blood countwould be an assessment of the skin lesions in terms of how disparate they are and [whether] there are any hints of blood involvement, cytopenias, leukocytosis with blasts, or bone marrow aspirate biopsy, because it would be the easiest way to make a diagnosis.

Evaluations of BPDCN

The molecular analysis by sequencing frequently identifies mutations in the typical older personkind of clonal hematopoiesis ASXL1 but also U2AF1 [and] things like TP53 [are] quite adverse, as well as occasionally IDH or IKZF1.

A PET CT is a good idea if [the clinician] suspects there is extensive extramedullary disease or adenopathy [theyd] like to follow. [There is also a recommendation for] diagnostic lumbar puncture at the time of diagnosis, but we typically do it at the time of relapse.

The [National Comprehensive Cancer Networks] set of guidelines for the evaluation and workup drives home the characteristic findings on histopathology, immunohistochemistry, and flow cytometry.6 Of course, if [someone is] in a center where this disease is uncommon, its certainly worthwhile to speak to [clinicians] who have experience with it and have participated in some of the trials or used the licensed medication.

In the peripheral blood, these cells look a little [like] lymphoid. Its common to find peripheral blood involvement in this disease, although maybe not quite in the leukemic phase. As Ive described before, these blasts are large, nuclear chromatin is open, nuclei are typically present, and the cytoplasm is not granular, so it doesnt look like myeloid leukemia. [However], monocytic leukemia can look similar and typically doesnt have much in the way of granulesand there are no vacuoles, so its not like Burkitt lymphoma.

There is no particular characteristic of a cytogenetic abnormality in BPDCN, but there are abnormalities [such as] deletions of the monosomy 5 and 6 or 13 and 15. The molecular abnormalities are also varied, and findings in a common older patient [can include] TET2 and ASXL1. But TP53, the adverse finding, is also common, as well as occasionally NPM1.

CD123 is a perfect marker because its present in over 95% of patients cells in the malignant neoplasm, and it is not so heavily expressed on healthy cells.7 This also has constituted a target for therapy because of the relative distribution of that marker on neoplastic cells, but there arent typical T-cell or B-cell markers.8

Treatment Paradigm in BPDCN

Tagraxofusp [Elzonris] is a typical immunotoxin and a CD123-directed antibody. That CD123 is the IL-3 alpha receptor, and attached to it is a payload of truncated diphtheria toxin, which is delivered into the cell that has this receptor. Its a first-in-class CD123-targeted immunotherapeutic and is FDA approved for [the] treatment of [patients with] BPDCN.9

Patients who have impaired performance status can get other treatments like localized treatment [such as] radiation or venetoclax-based therapy. Somebody who is protein malnourished would not be a candidate for tagraxofusp because this drug causes capillary leak, so there is a warning in the label, and patients with serum albumin less than 3.2 g/dL are not eligible for treatment. [However], on that treatment with steroids, they can get their albumin to improve by improving their performance status [and] increasing their appetite and food intake.

[The approval for the therapy came from the] multicenter, 4-stage, single arm, phase 1/2 trial [NCT02113982] evaluating this drug as monotherapy in patients with first-line or relapsed/refractory BPDCN, administered via intravenous infusion daily from day 1 through 5 for a 21-day cycle.10

The key eligibility criteria for the trial included albumin greater than or equal to 3.2 g/dL, age greater than or equal to 18 [years], a reasonably good performance status of less than or equal to 2, and adequate organ function. The primary end point was a combined rate of complete remission [CR] and CR with residual skin abnormality [CRc] in first-line patients.

The secondary end point was the duration or response [of treatment] and CR with residual skin abnormality not indicative of active disease. Some of these patients will have resolution of the nodule, but pigmentation that might remain, which didnt exclude them from being complete remitters.

Twenty-nine patients were previously untreated in the first line, the overall response rate [ORR] was 90% in stages 1 to 3, and the CR and CRc rate was 72%. Of those previously treated, many had more than 1 line of therapy, [with] some even having more than 4 lines of therapy.

Overall, the ORR was 75%, and many of these patients went on to stem cell transplant, but the impact of the drug on survival is harder to assess when you use allogeneic stem cell transplant as a consolidated maneuver.

[However], the overall likelihood of remaining in remission at 2 years was [approximately] 50% of those who went into remission. The median duration of CR and CRc was less than 3 years, and the median overall survival for all patients [was 8.2 months (95% CI, 4.1-11.9)].

Adverse Events With Tagraxofusp

The adverse event [AE] profile is important [with this therapy], and AEs occurring in at least 20% of patients included transaminase elevations [64%], peripheral edema [42%], weight increase [35%], hypokalemia [20%], and hypocalcemia [20%].

AEs that led to discontinuation were predominantly the capillary leak syndrome type, an increase in weight, and a decrease in albumin. [However], AST [aspartate aminotransferase] and ALT [alanine aminotransferase] increase also led to discontinuations.

Fortunately, discontinuations were not common on the trial, with only 6 of 89 [patients]. Again, however, to point out for those who had at least 1 grade greater than or equal to grade 3, treatment-emergent AEs were identified in 75 of 89 patients, with the most common grade 3 or great AEs [being] thrombocytopenia and [fewer] AST and ALT increases.

The overall incidence of capillary leak syndrome was high, over 50%. Most were grade 1 to 2 and resolved but some were not, including 2 fatal events, so you need to watch this. The first cycle must be given in the hospital. Common signs and symptoms include hypoalbuminemia, edema, weight gain, and hypotension.

Before initiating therapy, make sure the patient has adequate cardiac function and that the serum albumin is over 3.2 g/dL. During treatment, ensure that serum albumin levels stay above 3.5 g/dL and have not dropped by more than half an albumin level prior to initiation of each dose. Assess for signs and symptoms of capillary leaks, such as weight gain, new onset or worsening edema, pulmonary edema, hypotension, [and] hemodynamic instability. Seek medical advice if you see any of these things.

REFERENCES

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi:10.1182/blood-2016-03-643544

Deconinck E, Petrella T, Garnache Ottou F. Blastic plasmacytoid dendritic cell neoplasm: clinical presentation and diagnosis. Hematol Oncol Clin North Am. 2020;34(3):491-500. doi:10.1016/j.hoc.2020.01.010

Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14(4):220-222.

Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169(3):579-586. doi:10.1111/bjd.12412

Pemmaraju N, Wilson NR, Khoury JD, et al. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021;138(15):1373-1377. doi:10.1182/blood.2021011817

NCCN. Clinical Practice Guidelines in Oncology. Blastic plasmacytoid dendritic cell neoplasm, version 2.2022. Accessed February 22, 2023. https:// bit.ly/3ZgDzbM

Molina Castro D, Perilla Surez O, Cuervo-Sierra J, Moreno A. Blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report. Cureus. 2022;14(4):e23888. doi:10.7759/cureus.23888

Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628-1637. doi:10.1056/ NEJMoa1815105

FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. FDA. December 26, 2018. Accessed February 22, 2023. https:// bit.ly/3YWJ5Rb

Pemmaraju N, Sweet KL, Stein AS, et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2022;40(26):3032-3036. doi:10.1200/JCO.22.00034

See the article here:
Clinical Commentary: Addressing Treatment Tactics in Blastic ... - Targeted Oncology

Expert Tips on Alopecia Management From AAD 2023 – Dermatology Times

Scarring alopecia, stem cells, exosomes, and frontal fibrosing alopecia (FFA) were all hot topics of discussion during Ronda Farahs, MD,FAAD, multiple alopecia sessions at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans, Louisiana.

Farah, associate professor of dermatology at the University of Minnesota, cosmetic lead at the University of Minnesota Health clinics, and director of medical dermatology at the University of Minnesota Health Maple Grove Medical Center, discussed alopecia in-depth at her AAD sessions: Cosmetic and Procedural Interventions for Scarring Alopecia, Stem Cells & Exosomes, and Cosmetics and FFA: Approach to Managing Facial Papules and Hyperpigmentation.

Transcript

Ronda Farah, MD, FAAD: Hi, I'm Dr. Ronda Farah. I'm a dermatologist at the University of Minnesota, associate professor. I'm also the University of Minnesota Health cosmetic lead and I'm the director of the Maple Grove Medical Center. I'm also working with the American Academy of Dermatology on social media.

Dermatology Times: What pearls did you share in your session, "Cosmetics and FAA: Approach to Managing Facial Papules and Hyperpigmentation?"

Farah: The cosmetics and frontal fibrosing alopecia talk is really focused for me on the forehead area. In the frontal fibrosing alopecia patient population, I try to keep the skin product away from the hair follicle as much as possible. I ask my patients not to apply that product directly on the hair follicle. Try to also keep sunscreens away unless they're non nanoparticle-based sunscreens, although we don't really know what the final verdict is going to be on sunscreens and I'm also leaning towards more physical-based sunscreens. And in addition to that, talking a little bit about the veins, the new article that came out in the JAAD and the utilization of this device on the forehead veins, which can become very prominent in frontal fibrosing alopecia and I think gently putting those out at the initial visit so that patients are aware those are typically there before they even start steroid injections. I am still utilizing some botulinumtoxin in frontal fibrosing alopecia. I do think that botulinumtoxin has been reported to cause depressions in the scalp so counseling patients on that, because knowing they can also have depressions from their scalp from frontal fibrosing alopecia is important. Also to limit that change in skin texture from the scalp at the front to lower down, I really work on removing seborrheic keratosis and sebaceous hyperplasia using topical tretinoin and oral isotretinoin, although that does have limited data to kind of help with that the facial papule appearance. Those are some of my big pearls for that talk.

Dermatology Times: What are the important takeaways from your session, "Cosmetic and Procedural Interventions for Scarring Alopecia?"

Farah: That session was great. We focused on scarring alopecia, we talked about using platelet rich plasma off-label which could be helpful, as there are case series and case reports. We talked a little bit about exosomes, which do not have strong medical evidence and will be marketed to you, including scalp serums. Lacking medical evidence, only one clinical study, I was able to identify to date that included a microneedle really muddying the waters, not FDA approved for injection, we are not using it. And then we also talked a little bit about photobiomodulation. That's off-label for darker skin types, but could be helpful in that population in our study.

Dermatology Times: What do you hope fellow physicians take away from your session, "Stem Cells & Exosomes?"

Farah: I'm passionate about exosomes because we performed a literature review. Two of the papers involved a human subject: one was just an abstract, the other one utilized a microneedle. That made it difficult in the second one to figure out if it was actually the microneedle or if it was the exosomes. All the other studies were pretty clinical. They were all in mice. They were promising, but they don't reach our level of evidence for evidence-based medicine. Exosomes are not FDA-approved to inject in the United States. There are reports of bacteremia, inflammation, blindness, neurologic issues, contamination with viruses, and concern for hepatitis C and HIV. People wonder if you can use exosomes topically, I wondered that too. From what I can make from my understanding, And again, I'm not a lawyer, but of these exposome products, they can be human. And if they're topical, they might get marketed to physicians and other clinicians as "Oh, well, it's topical, so you can use it." Well, maybe that is true. That seems like that might be true. Again, I'm not a lawyer, but those seem to not necessarily be regulated by the FDA. So, we're applying human product that's not necessarily regulated by the FDA. So, who's responsible for the product then? And from what I can understand, it appears to be the manufacturer. And so, if the manufacturer is not handling the human product correctly, or the manufacturer is outside the United States, that can make it difficult for a US patient. So, at this time, I do not recommend topical or injectable exosomes to my patients. I think it's a lot of items on the topical side that probably need some work, and my job is to discuss higher levels of medical evidence, although they do seem promising. We're working towards a study once we eventually have an investigational new drug application. So, I think exosomes could be exciting. But they're not something I would promote for hair growth. And you should also be aware as clinicians that the CDC has posted a "how-to" for patients on how to spot doctors or other types of clinicians who are telling you that they're doing a study on you with exosomes. So that is out there teaching the patient how to identify people who might be. And I'm not saying that this is happening. I just saw that the CDC had spent time developing that page. I'm not clear enough if that's happening. So, for me, it's about evidence-based medicine, and that's why I'm passionate about the exosomes topic.

[Transcript edited for clarity]

Go here to see the original:
Expert Tips on Alopecia Management From AAD 2023 - Dermatology Times

Moorfields Eye Hospital surgeon saves the vision and the career … – Ophthalmology Times

(Image Credit: AdobeStock/Fukume)

A Moorfields Eye Hospital ophthalmologist has performed a life-changing surgery on a 23-year-old patient after diagnosing him with a progressive eye disease that is prevalent in Middle Eastern communities.

Mogemad Osama, an Ajman University student from Palestine who plans to become a dentist, struggled for years with devastating vision loss which caused him to change his prescription glasses multiple times. After deciding that he needed to seek help, Osama was referred to Esmaeil Arbabi, MD, at MoorfieldsEye Hospital, a Mubadala Health partner.

According to a Moorfields Eye Hospital news release, Osama feared he would not be able to realize his dream of practicing dentistry.

My career depends on two things: my eyes and my hands, he said in the news release. When I first started having problems with my vision, it was a huge disappointment for me. But I never give up.

Osama was soon diagnosed with keratoconus, which affects the structure of the cornea and gradually causes blurred vision that cannot be corrected with glasses. The eye hospital noted in the news release a recent study found while the disease affects only one in 2,000 people worldwide, the prevalence of the disease in the United Arab Emirates (UAE) is 2.7 percent, which is 54 percent higher than the global average, according to the hospitals news release. The condition also impacts both men and women and typically stabilizes by the time people reach their 30s, although by then serious damage could have been caused.

Mogemad Osama and Esmaeil Arbabi, MD. (Image courtesy of Moorfields Eye Hospital)

According to Arbabi, who has treated a number of cases of keratoconus, the cause of the disease is unknown, but genetics and environmental factors could play a role. Osamas father had surgery several years ago for the same condition.

Instead of opting for a corneal transplant, Arbabi performed cross-linking, combined with a sophisticated laser treatment on Osamas left eye. The advanced laser reshapes the cornea and smoothens the irregularities caused by keratoconus. This will then be immediately followed by the application of Vitamin B eyedrops and shining of an ultraviolet light on the eye. The procedure only takes just 15 minutes to complete and has a 95 percent chance in stopping the progression of the disease.

Early diagnosis and early treatment are absolutely essential, Arbabi in the news release. If we catch this early enough, we can treat it so that its like nothing has happened at all. But if you delay, theres a risk of a lifetime wearing hard, rigid contact lenses, or ultimately requiring a corneal transplant. It could lead to a poor quality of life for the rest of your life.

Before the procedure I was experiencing double vision; it wasnt clear at all, said Osama. But 10 days after, everything in my left eye was back to normal. I even returned to university and started to work again. It would be fair to say that my career has been saved by Dr. Arbabi and the great staff at Moorfields.

The disease will be the focus of the 1st Annual International Keratoconus Academy (IKA) of Eye Care Professionals Keratoconus Symposium will take place April 22-23, 2023, at the Scottsdale Marriott at McDowell Mountains in Scottsdale, Arizona.

This new hybrid, interactive conference for optometrists, ophthalmologists, and other eye care professionals involved in keratoconus management will promote ongoing professional education and scientific development in keratoconus and other forms of corneal ectasia. The topics covered will include using new diagnostic technologies, maximizing keratoconus management in clinical practice, and amplifying clinician voices on keratoconus best practices.

The co-chairs of the event are IKA CEO and cofounder S. Barry Eiden, OD, FAAO, FSLS, North Suburban Vision Consultants, Deerfield, Illinois; IKA president and cofounder Andrew S. Morgenstern, OD, FAAO, FNAP, Walter Reed National Military Medical Center, Bethesda, Maryland; and IKA executive board member Elizabeth Yeu, MD, Virginia Eye Consultants, Norfolk.

The 1st annual IKA Keratoconus Symposium will be [a gathering] of some of the greatest minds in the field of keratoconus who will share their extensive knowledge and experience regarding the most current information available and their visions toward the future,Eiden commented.

Registration is free for students, residents, fellows, active duty service members, and veterans.

Read more:
Moorfields Eye Hospital surgeon saves the vision and the career ... - Ophthalmology Times

Safety and efficacy of co-administration of CD19 and CD22 CAR-T … – Journal of Translational Medicine

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:150717.

Article PubMed PubMed Central Google Scholar

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med. 2018;378:43948.

Article CAS PubMed PubMed Central Google Scholar

Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022;40:93244.

Article CAS PubMed Google Scholar

Barz Leahy A, Stanley KJ, Myers RM, DiNofia AM, Wray L, Rheingold SR, Callahan C, Baniewicz D, Barry AE, Patino MM, et al. Cytogenetic characteristics and outcomes of patients receiving CTL019 CAR T cell therapy. Blood. 2019;134:14641464.

Article Google Scholar

Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu Y, Tu S, Li Y. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664.

Article CAS PubMed PubMed Central Google Scholar

Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM, Vakil A, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood. 2021;137:32335.

Article CAS PubMed PubMed Central Google Scholar

Holland EM, Molina JC, Dede K, Moyer D, Zhou T, Yuan CM, Wang HW, Stetler-Stevenson M, Mackall C, Fry TJ, et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. J Immunother Cancer. 2022;10:e004483.

Article PubMed PubMed Central Google Scholar

Wudhikarn K, Flynn JR, Rivire I, Gnen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, et al. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 2021;138:53143.

Article CAS PubMed PubMed Central Google Scholar

Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, et al. Antigen-independent activation enhances the efficacy of 41BB-costimulated CD22 CAR T cells. Nat Med. 2021;27:84250.

Article CAS PubMed PubMed Central Google Scholar

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:208.

Article CAS PubMed Google Scholar

Wei G, Zhang Y, Zhao H, Wang Y, Liu Y, Liang B, Wang X, Xu H, Cui J, Wu W, et al. CD19/CD22 dual-targeted CAR T-cell therapy for relapsed/refractory aggressive b-cell lymphoma: a safety and efficacy study. Cancer Immunol Res. 2021;9:106170.

Article CAS PubMed Google Scholar

Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13:30.

Article PubMed PubMed Central Google Scholar

Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuc G, Landoni E, Sun C, Chen Y, Savoldo B, Dotti G. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2:90418.

Article CAS PubMed PubMed Central Google Scholar

Cronk RJ, Zurko J, Shah NN. Bispecific chimeric antigen receptor T cell therapy for B cell malignancies and multiple myeloma. Cancers. 2020;12:2523.

Article CAS PubMed PubMed Central Google Scholar

Xie B, Li Z, Zhou J, Wang W. Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies. Cancers. 2022;14:3230.

Article CAS PubMed PubMed Central Google Scholar

Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, Xie Z, Qiao X, Jiang H, Shao J, et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter phase II trial. J Clin Oncol. 2022;2:01214.

Google Scholar

Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, Wolters PL, Steinberg SM, Baker EH, Delbrook CP, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39:16509.

Article CAS PubMed PubMed Central Google Scholar

Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, Liu Z, Zhang Y, Qu X, Zhang Y, et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019;33:285466.

Article CAS PubMed Google Scholar

Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 car T-cell trial. J Clin Oncol. 2020;38:193850.

Article CAS PubMed PubMed Central Google Scholar

Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, Vora A, Bonney D, Veys P, Rao K, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021;27:1797805.

Article CAS PubMed PubMed Central Google Scholar

Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, Ligon JA, Silbert S, DD K, Benzaoui M, et al. CD19/22 CAR T-cells in children and young adults with B-ALL: phase I results and development of a novel bicistronic CAR. Blood. 2022;140:451.

Article CAS PubMed Google Scholar

Kantarjian H, Stein A, Gkbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Fo R, Bassan R, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:83647.

Article CAS PubMed PubMed Central Google Scholar

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:62538.

Article CAS Google Scholar

Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 14 June 2010.

Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol. 2020;9:15.

Article CAS PubMed PubMed Central Google Scholar

Pabst T, Joncourt R, Shumilov E, Heini A, Wiedemann G, Legros M, Seipel K, Schild C, Jalowiec K, Mansouri Taleghani B, et al. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. Exp Hematol. 2020;88:7-14.e13.

Article CAS PubMed Google Scholar

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, OConnor RS, Hwang WT, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:56371.

Article CAS PubMed PubMed Central Google Scholar

Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, Patel S, Kleinsorge Block S, Schiavone J, Zamborsky K, et al. Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-hodgkin lymphoma. Front Immunol. 2021;12: 745320.

Article CAS PubMed PubMed Central Google Scholar

Sang W, Shi M, Yang J, Cao J, Xu L, Yan D, Yao M, Liu H, Li W, Zhang B, et al. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. 2020;9:582738.

Article CAS PubMed PubMed Central Google Scholar

Jiang Z, Liao R, Lv J, Li S, Zheng D, Qin L, Wu D, Chen S, Long Y, Wu Q, et al. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia. 2021;35:138091.

Article CAS PubMed Google Scholar

Li P, Jiang Z, Liao R, Tang Z. Abstract 1427: IL6 trans-signaling robustly promotes the expansion and antitumor activity of CAR T cells. Can Res. 2019;79:14271427.

Article Google Scholar

Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris MR, Keating AK, Prabhu S, Pacenta HL, Phillips CL, Talano JA, et al. Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2022;7:541.

Article PubMed Central Google Scholar

Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:121926.

Article CAS PubMed Google Scholar

Qin H, Nguyen SM, Ramakrishna S, Tarun S, Yang L, Verdini NP, Haso W, Fry TJ. Novel CD19/CD22 bicistronic chimeric antigen receptors outperform single or bivalent cars in eradicating CD19+CD22+, CD19-, and CD22- Pre-B Leukemia. Blood. 2017;130:810.

Article Google Scholar

Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:332231.

Article CAS PubMed PubMed Central Google Scholar

Dourthe ME, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, Mchinaud F, Grain A, Chaillou D, Rahal I, Caillat-Zucman S, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021;35:338393.

Article CAS PubMed Google Scholar

Schultz LM, Czerwinski DK, Levy R, Levy S. CD81 costimulation skews CAR transduction toward naive T cells. Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):e1910844119.

Article CAS PubMed PubMed Central Google Scholar

Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18:37993.

Article PubMed PubMed Central Google Scholar

Thudium Mueller K, Grupp SA, Maude SL, Levine JE, Pulsipher MA, Boyer MW, August KJ, Myers GD, Tam CS, Jaeger U, et al. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Adv. 2021;5:498091.

Article CAS PubMed PubMed Central Google Scholar

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:212338.

Article PubMed PubMed Central Google Scholar

Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, et al. Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol. 2021;39:304455.

Article CAS PubMed PubMed Central Google Scholar

An L, Lin Y, Deng B, Yin Z, Zhao D, Ling Z, Wu T, Zhao Y, Chang AH, Tong C, Liu S. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. BMC Cancer. 2022;22:393.

Article CAS PubMed PubMed Central Google Scholar

See the rest here:
Safety and efficacy of co-administration of CD19 and CD22 CAR-T ... - Journal of Translational Medicine

NKY community helping raise money for mother and teacher in need of lifesaving surgery – WKRC TV Cincinnati

NKY community helping raise money for mother and teacher in need of lifesaving surgery

NKY community helping raise money for mother and teacher in need of lifesaving surgery (Lindsey Hughes)

FORT MITCHELL, Ky. (WKRC) - A Northern Kentucky mother and teacher needs help covering the cost of a highly-expensive, but lifesaving medical procedure.

NKY community helping raise money for mother and teacher in need of lifesaving surgery (WKRC, Lindsey Hughes)

A fundraiser was held Sunday afternoon at The Braxton Barrel House for Lindsey Hughes. She's battlingsystemic scleroderma, a rare autoimmune disease.

Hughes is a teacher at Beechwood High School, and a new mother.

NKY community helping raise money for mother and teacher in need of lifesaving surgery (Lindsey Hughes)

In October 2022, after years of suffering, doctors diagnosed her with the disease. It affects her skin and internal organs.

"I went up to the University of Michigan. There's a scleroderma center and the doctors there told me if I want to be able to see my daughter grow up and live a functional life again, I need a stem cell transplant, said Hughes.

Hughes says both the University of Michigan and the Mayo Clinic have approved her for the transplant. She's currently going through pre-transplant testing.

NKY community helping raise money for mother and teacher in need of lifesaving surgery (Lindsey Hughes)

With the price of the procedure starting at $250,000, it's unclear what, if any, help insurance will be.

Thanks to donations and fundraisers, Hughes is getting closer to covering the cost that she hopes will give her future quality time with her family and friends.

"I feel great today. Physically, Im exhausted, but its been so amazing to see friends and family come out to give support, she said.

For more information about Hughes and how you can help, check out the Facebook page about her journey and her GoFundMe campaign.

See the original post:
NKY community helping raise money for mother and teacher in need of lifesaving surgery - WKRC TV Cincinnati

New Insights on Treating Neurodegeneretive Diseases Could Lead … – MarketScale

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimers in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimers disease medications are giving new options to patients.

Alzheimers research is getting to a place where cancer research was maybe 30, 40 years ago, says Anton Porsteinsson, MD, director of the Alzheimers Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. I think were at a point where were going to see a logarithmic increase in discovery.

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dungs Thoughts

Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimers disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinsons disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best weve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently.

Article written by Sonya Young.

Continued here:
New Insights on Treating Neurodegeneretive Diseases Could Lead ... - MarketScale

Hospital Acquired Disease Testing Market, Size is estimated to be US$ 14.91 billion by 2030 with a CAGR of – EIN News

Hospital Acquired Disease Testing Market - PMI

The report "Hospital Acquired Disease Testing Market, By Test Type - Trends, Analysis and Forecast till 2029.

Key Highlights:

In December 2021, the healthians and QRX launch rapid PCR covid test with turnaround time of 30 minutes.

Analyst View:

The rise of hospital acquired diseases is fueled by poor infection control techniques and procedures at healthcare facilities, as well as filthy and non-sterile environmental surfaces, which is propelling the hospital acquired disease testing market forward. Furthermore, rising antibiotic resistance as a result of enhanced medical treatment leads to the development of hospital-acquired infections, which fuels market expansion. Furthermore, the market is being driven by the rising occurrence of nosocomial infections such as surgical wounds, urinary tract infections, and lower respiratory tract infections in intensive care units, orthopedics, and acute surgical wards.

Improper infection control practices and procedures at healthcare center Improper infection control practices and procedures at healthcare center and unclean and non-sterile environmental surfaces lead to development of hospital acquired diseases, which is driving growth of the hospital acquired disease testing market. Furthermore, increasing antibiotic resistance due to adoption of advanced medical care results into development of hospital acquired diseases, which in turn is fueling growth of the market. Moreover, increasing prevalence of nosocomial infections such as surgical wounds, urinary tract infections, and lower respiratory tract infections in intensive care units, orthopedic, and acute surgical ward are driving growth of the market. Hospital acquired infection is a major burden for society, patients, and healthcare management. Increasing awareness among population regarding hospital acquired infections, adoption of infection control programs by healthcare facilities, maintaining personal hygiene by the hospital staff, complete sterilization of medical equipment, and a clean sanitary environment in the health care facilities may restrain growth of the hospital acquired disease testing market.

Get a Sample Copy of the Hospital Acquired Disease Testing Market: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/98

Key Market Insights from the report:

Hospital Acquired Disease Testing Market accounted for US$ 7.2 billion in 2020 and is estimated to be US$ 14.91 billion by 2030 and is anticipated to register a CAGR of 7.6%. Global Hospital Acquired Disease testing market is segmented into test type and region. Based on Test Type, the Global Hospital Acquired Disease Testing Market is segmented into Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others. By Region, the Global Hospital Acquired Disease Testing Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Hospital Acquired Disease Testing Market:

The key players in the global Hospital Acquired Disease Testing market includes; Diatherix laboratories Life technologies Cantel Medical Corporation Meridian Biosciences Qiagen GmbH Nordion Roche Cepheid

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Some Important Points Answered in this Market Report Are Given Below: Explains an overview of the product portfolio, including product development, planning, and positioning Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies. Detailed analysis of the market revenue over the forecasted period. Examining various outlooks of the market with the help of Porters five forces analysis, PEST & SWOT Analysis. Study on the segments that are anticipated to dominate the market. Study on the regional analysis that is expected to register the highest growth over the forecast period

Get Free PDF Download of Hospital Acquired Disease Testing Market: https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/98

Market Segmentation:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Hospital Acquired Disease Testing Market report based on Test Type and Region.

By Test Type - Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others

Regional Insights:

On the basis of region, the global plant stem cells market finds its scope in North America, Europe, Latin America, Asia Pacific, Middle East and Africa. India hospital acquired infection diagnostics market is predicted to rise significantly due to rising occurrence of nosocomial illnesses such as surgical site infections and bloodstream infections. After completing a study on 10,835 patients in diverse clinical settings, India observed a 4.4 percent overall growth rate for hospital acquired illnesses, according to the Indian Journal of Basic and Applied Medical Research.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Topics Related:

Oncology Molecular Diagnostics Market, By Product (Reagents, Instruments, and Others), By Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, and Others), By Technology (In-Situ Hybridization, Polymerase Chain Reaction (PCR), Next Generation Sequencing, Spectrometry, Transcription Mediated Amplification, and Others), By End-Users (Diagnostic Centers, Hospitals, Academic & Research Institutes, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Influenza Diagnostics Market, By Type (RT-PCR, Viral Culture, Antigen Detection Tests, Serological Assays, Simple Amplification-based Assays, Molecular Assays, and Others) By End-Users (Hospitals, Clinics, Diagnostic Laboratories and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Shweta RaskarProphecy Market Insights+1 860-531-2701email us hereVisit us on social media:FacebookTwitterLinkedIn

Read this article:
Hospital Acquired Disease Testing Market, Size is estimated to be US$ 14.91 billion by 2030 with a CAGR of - EIN News